se of Intravenous magnesium sulphate in children with acute severe asthma
Not Applicable
- Conditions
- Health Condition 1: J960- Acute respiratory failure
- Registration Number
- CTRI/2023/01/049011
- Lead Sponsor
- Surya Mother and Child Superspeciality hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children between 2- 16 years of age with moderate to severe acute asthma defined as PRAM (Pediatric respiratory assessment measure) score > 5 inspite of first line therapy with short acting beta agonists and corticosteroids.
Exclusion Criteria
1.First episode of wheezing or alternative diagnosis like foreign body aspiration.
2.Coexisting pneumonia defined as radiological abnormalities like infiltrates or opacities on chest Roentgenogram.
3.Patients needing ventilator support.
4.Patients who have underlying cardiac, renal, neurologic or pulmonary dysfunction contraindicating the use of magnesium sulphate or aminophylline
5.Known hypersensitivity to Magnesium sulphate or aminophylline.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Reduction in asthma severity as measured by PRAM (Pediatric Respiratory Assessment Measure) score at 60 mins, 120 mins and 4 hours, 6 hrs, 12 hours and 24 hours after initiating therapy.Timepoint: 1. Reduction in asthma severity as measured by PRAM (Pediatric Respiratory Assessment Measure) score at 60 mins, 120 mins and 4 hours, 6 hrs, 12 hours and 24 hours after initiating therapy.
- Secondary Outcome Measures
Name Time Method a.Length of ICU stay <br/ ><br>b.Duration of oxygen support <br/ ><br>c.Need for NIV <br/ ><br>d.Need for HFNC <br/ ><br>e.Need for invasive mechanical <br/ ><br>f.Mortality <br/ ><br>g.Adverse events such as tachycardia, GI bleeding, vomiting, need for vasoactive agents <br/ ><br>Timepoint: whole length of hospital stay